Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DoseBiome was a Toronto-based biotechnology company specializing in oral microbiome research and consumer health products. Founded in 2016 and incubated at JLABS @ Toronto, the company's flagship product was "qii," a functional tea beverage formulated to maintain a neutral oral pH and reduce dental plaque. The drink utilized a proprietary xylitol-based composition called XyVita to selectively inhibit harmful bacteria like Streptococcus mutans while supporting a healthy microbial balance. Although the company successfully commercialized its products in North America and received backing from major investors like Horizons Ventures, it has since ceased operations and is currently classified as inactive.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DoseBiome.